Clinical Efficacy of Keyhole Surgery for Intracranial Tumors, and Its Effect on Tumor-Specific Growth Factors

Abstract

Objective: To determine the clinical efficacy of keyhole surgery for intracranial tumors, and its effect on tumor-specific growth factors. Methods: In this retrospective study, clinical data of 86 patients with intracranial tumors admitted to our hospital between April 2019 and April 2022 were analyzed. The patients were assigned to either an observation group that received traditional craniotomy, or an experimental group treated with keyhole surgery. The indices of outcome measured were perioperative indices, clinical efficacy, cerebrospinal fluid neuropeptide level, tumor-specific growth factor level, inflammatory factor levels, and complications. Results: The experimental group had shorter operative time, lower volume of intraoperative bleeding, shorter hospital stay and higher treatment efficiency than the observation group (p < 0.05). The experimental group had markedly higher levels of oxytocin (OT), arginine vasopressin (AVP), and beta-endorphin (β-EP), and lower levels of tumor-supplied group factor (TSGF), C-reactive protein (CRP) and tumor necrosis factor-α (TNF-α), than the observation group (p < 0.05). There was a lower incidence of complications in the experimental group than in the observation group (p < 0.05). Conclusions: Keyhole surgery effectively reduced operation time, volume of intraoperative bleeding, and levels of tumor-specific growth factor and inflammatory factors, and it improved levels of cerebrospinal fluid neuropeptide in patients with intracranial tumors.